Market Overview:
The global hypoxia inducible factor 1 alpha inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of cancer, rising awareness about cancer treatment options, and technological advancements in the field of oncology. The global hypoxia inducible factor 1 alpha inhibitor market is segmented by type into BC-001, CASI-2ME2, CRLX-101, and others. By application, the market is segmented into solid tumor, acute myelocytic leukemia (AML), colorectal cancer (CRC), and others. By region, the market is segmented into North America, Latin America Europe Asia Pacific and Middle East & Africa.
Product Definition:
Hypoxia Inducible Factor 1 Alpha Inhibitor is a protein that inhibits the function of Hypoxia Inducible Factor 1 Alpha (HIF-1α). HIF-1α is responsible for the transcription of genes involved in oxygen metabolism and angiogenesis. By inhibiting HIF-1α, Hypoxia Inducible Factor 1 Alpha Inhibitor reduces the ability of cells to adapt to hypoxic conditions. This makes it useful as a cancer therapy, as cancer cells often rely on hypoxic conditions to survive.
BC-001:
Hypoxia Inducible Factor 1 Alpha (HIF-1) is a protein that regulates the expression of genes involved in cellular respiration under hypoxic conditions. HIF-1 acts as an inhibitor and prevents the release of other inhibitors from mRNAs. The binding of BC-001 to the site blocks this inhibition, resulting in increased levels of mRNAs coding for cytoprotective proteins such as Bcl2, Bcl6, and Badh3.
CASI-2ME2:
CASI-2ME2 is a selective inhibitor of HIF1A. It has been reported to have more potency than the reference drug, Proteus mirabilis polysaccharide (PMP) in inhibiting hypoxia-inducible factor 1 alpha (HIF1A). CASI-2ME2 has also been found to be effective in vitro and in vivo against other human lung cancer cell lines besides NSCLC.
Application Insights:
Solid tumor accounted for the largest share in 2016 owing to the availability of effective treatment options such as chemotherapy and hypoxic therapy. Increasing prevalence of cancer worldwide is expected to be a major factor driving this segment during the forecast period. According to WHO, it has been estimated that globally 1 in 6 women and 1 in 5 men are estimated to develop cancer during their life span. Thus, increasing incidence rates coupled with rising awareness about early diagnosis is anticipated fuel market growth over the forecast period.
Regional Analysis:
North America was the largest revenue generating region in 2017. The growth is attributed to the presence of a substantial number of global players, high adoption rate for novel therapeutics and increasing government funding for cancer research. In addition, favorable reimbursement policies are also expected to drive market growth over the forecast period. Asia Pacific is estimated to be fastest growing region during the forecast period due to rising awareness about HIF1A INHIBITORS and availability of effective treatment methods against this condition in emerging countries such as China & India & South Korea etc. Moreover, increasing healthcare expenditure by governments and rise in disposable income will boost regional market development further on account of rapid economic development coupled with improving living standards among middle class population groups leading towards urbanization across these regions will have a positive impact on overall demand over next seven years as well (Figure 1).
Growth Factors:
- Increasing prevalence of cancer: The increasing prevalence of cancer is one of the key growth drivers for the hypoxia inducible factor 1 alpha inhibitor market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing incidence rate of cancer is expected to drive demand for hypoxia inducible factor 1 alpha inhibitors over the forecast period.
- Rising awareness about HIF-1 inhibitors: There is a rising awareness among physicians and patients about HIF-1 inhibitors and their potential benefits over traditional chemotherapy drugs used for treating various cancers such as renal cell carcinoma (RCC), non-small cell lung carcinoma (NSCLC), and glioblastoma multiforme (GBM). This growing awareness is expected to boost demand for these drugs over the forecast period.
- Technological advancements: The development of novel technologies such as next generation sequencing (NGS) has led to identification of new targets involved in tumorigenesis which can be inhibited by HIF-1alpha inhibitors thereby providing an impetus to this market’s growth prospects . For instance, In February 2017, AstraZeneca announced that its investigational drug selumetinib was granted Breakthrough Therapy Designation by FDA for treatment naïve patients with advanced NRAS mutated
Scope Of The Report
Report Attributes
Report Details
Report Title
Hypoxia Inducible Factor 1 Alpha Inhibitor Market Research Report
By Type
BC-001, CASI-2ME2, CRLX-101, Others
By Application
Solid Tumor, Acute Myelocytic Leukemia, Colorectal Cancer, Others
By Companies
Aileron Therapeutics, Inc., CASI Pharmaceuticals Inc., Cerulean Pharma, Inc., F. Hoffmann-La Roche Ltd., InterMed Discovery GmbH, OncoImmune, Inc., Peloton Therapeutics, Inc., RXi Pharmaceuticals Corporation, Sorrento Therapeutics, Inc., Transcriptogen Ltd, Vascular Biogenics Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Report Segments:
The global Hypoxia Inducible Factor 1 Alpha Inhibitor market is segmented on the basis of:
Types
BC-001, CASI-2ME2, CRLX-101, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Solid Tumor, Acute Myelocytic Leukemia, Colorectal Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aileron Therapeutics, Inc.
- CASI Pharmaceuticals Inc.
- Cerulean Pharma, Inc.
- F. Hoffmann-La Roche Ltd.
- InterMed Discovery GmbH
- OncoImmune, Inc.
- Peloton Therapeutics, Inc.
- RXi Pharmaceuticals Corporation
- Sorrento Therapeutics, Inc.
- Transcriptogen Ltd
- Vascular Biogenics Ltd.
Highlights of The Hypoxia Inducible Factor 1 Alpha Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BC-001
- CASI-2ME2
- CRLX-101
- Others
- By Application:
- Solid Tumor
- Acute Myelocytic Leukemia
- Colorectal Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hypoxia Inducible Factor 1 Alpha Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hypoxia Inducible Factor 1 Alpha Inhibitor (HIF1A inhibitor) is a type of medication that helps to block the action of HIF1A, which is responsible for inducing hypoxia in cells. This can help to prevent or reduce the severity and duration of hypoxic conditions such as altitude sickness.
Some of the major players in the hypoxia inducible factor 1 alpha inhibitor market are Aileron Therapeutics, Inc., CASI Pharmaceuticals Inc., Cerulean Pharma, Inc., F. Hoffmann-La Roche Ltd., InterMed Discovery GmbH, OncoImmune, Inc., Peloton Therapeutics, Inc., RXi Pharmaceuticals Corporation, Sorrento Therapeutics, Inc., Transcriptogen Ltd, Vascular Biogenics Ltd..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hypoxia Inducible Factor 1 Alpha Inhibitor Market - Supply Chain
4.5. Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Forecast
4.5.1. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Absolute $ Opportunity
5. Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Type
5.3.1. BC-001
5.3.2. CASI-2ME2
5.3.3. CRLX-101
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Application
6.3.1. Solid Tumor
6.3.2. Acute Myelocytic Leukemia
6.3.3. Colorectal Cancer
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hypoxia Inducible Factor 1 Alpha Inhibitor Demand Share Forecast, 2019-2026
9. North America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Application
9.4.1. Solid Tumor
9.4.2. Acute Myelocytic Leukemia
9.4.3. Colorectal Cancer
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Type
9.7.1. BC-001
9.7.2. CASI-2ME2
9.7.3. CRLX-101
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hypoxia Inducible Factor 1 Alpha Inhibitor Demand Share Forecast, 2019-2026
10. Latin America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Application
10.4.1. Solid Tumor
10.4.2. Acute Myelocytic Leukemia
10.4.3. Colorectal Cancer
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Type
10.7.1. BC-001
10.7.2. CASI-2ME2
10.7.3. CRLX-101
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hypoxia Inducible Factor 1 Alpha Inhibitor Demand Share Forecast, 2019-2026
11. Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Application
11.4.1. Solid Tumor
11.4.2. Acute Myelocytic Leukemia
11.4.3. Colorectal Cancer
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Type
11.7.1. C-001
11.7.2. CASI-2ME2
11.7.3. CRLX-101
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Demand Share, 2019-2026
12. Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Application
12.4.1. Solid Tumor
12.4.2. Acute Myelocytic Leukemia
12.4.3. Colorectal Cancer
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Type
12.7.1. BC-001
12.7.2. CASI-2ME2
12.7.3. CRLX-101
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Demand Share, 2019-2026
13. Middle East & Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Application
13.4.1. Solid Tumor
13.4.2. Acute Myelocytic Leukemia
13.4.3. Colorectal Cancer
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size and Volume Forecast by Type
13.7.1. BC-001
13.7.2. CASI-2ME2
13.7.3. CRLX-101
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market: Market Share Analysis
14.2. Hypoxia Inducible Factor 1 Alpha Inhibitor Distributors and Customers
14.3. Hypoxia Inducible Factor 1 Alpha Inhibitor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aileron Therapeutics, Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CASI Pharmaceuticals Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cerulean Pharma, Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. F. Hoffmann-La Roche Ltd.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. InterMed Discovery GmbH
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. OncoImmune, Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Peloton Therapeutics, Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. RXi Pharmaceuticals Corporation
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Sorrento Therapeutics, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Transcriptogen Ltd
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Vascular Biogenics Ltd.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
